Agile therapeutics announces presentation of safety and efficacy data of twirla® (levonorgestrel and ethinyl estradiol) transdermal system in women of differing bmi categories at acog annual meeting

Princeton, n.j., april 30, 2021 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx), a women's healthcare company, today announced that a post hoc analysis of the phase 3 secure trial evaluating the safety and efficacy of twirla® (levonorgestrel and ethinyl estradiol) transdermal system in women with bmi < 25 kg/m2 and women with bmi 25-30 kg/m2 will be presented at the american college of obstetricians and gynecologists (acog) annual clinical and scientific meeting from april 30 – may 2.
AGRX Ratings Summary
AGRX Quant Ranking